Overall treatment failure, including mortality, thoracic surgery or referral for further fibrinolytic therapy · adult parapneumonic effusions and empyema
It is very uncertain whether fibrinolytics changes overall treatment failure, including mortality, thoracic surgery or… compared with placebo (very low certainty).
1 finding from 1 review
Overall mortality · critically ill participants with ALI and ARDS
INO showed no clear difference in overall mortality compared with control group (moderate certainty).
1 finding from 1 review
Overall mortality at 28 days · critically ill participants with ALI and ARDS
INO showed no clear difference in overall mortality at 28 days compared with control group (moderate certainty).
1 finding from 1 review
Mortality in paediatric population (subgroup) · critically ill participants with ALI and ARDS
INO showed no clear difference in mortality in paediatric population (subgroup) compared with control group (moderate certainty).
1 finding from 1 review
RR 0.78 [0.51, 1.18]
185 participants
Moderate
Mortality. · adult parapneumonic effusions and empyema
Fibrinolytics showed no clear difference in mortality. compared with placebo (moderate certainty).
1 finding from 1 review
All‐cause mortality · bleeding patients or at risk of severe bleeding
It is very uncertain whether fibrinogen concentrate changes mortality compared with any comparator (very low certainty).
1 finding from 1 review
All‐cause mortality · adults with low cardiac output syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · pulmonary hypertension in neonates
Sildenafil plus iNO showed no clear difference in all‐cause mortality compared with placebo plus iNO (low certainty).
1 finding from 1 review
All‐cause mortality at 28 days and before discharge from hospital · preterm born neonates
1 finding from 1 review
Perinatal mortality · women with gestational diabetes mellitus
1 finding from 1 review
All‐cause long‐term mortality · adults with cardiogenic shock
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · patients with chronic obstructive pulmonary disease
1 finding from 1 review
All‐cause mortality · patients with chronic obstructive pulmonary disease
1 finding from 1 review
All‐cause mortality at last · people with liver metastases
Summary of Findings Table ‐ Electrocoagulation in combination with… may leads to lower all‐cause mortality at last compared with control (vehicle solution of allopurinol by mouth) (low certainty).
1 finding from 1 review
Mortality Clinically · people with hepatic encephalopathy
Branched‐chain amino acids (BCAA) showed no clear difference in mortality Clinically compared with control (moderate certainty).
1 finding from 1 review
All‐cause mortality
It is very uncertain whether amino acid solution, alone or in combination with dextrose changes mortality compared with dextrose solution (very low certainty).
1 finding from 1 review
All‐cause short‐term mortality: at intensive care unit · adults with cardiogenic shock
It is very uncertain whether dopamine‐milrinone changes all‐cause short‐term mortality: at intensive care unit compared with dopamine‐dobutamine (very low certainty).
1 finding from 1 review
All‐cause mortality during hospital stay and all‐cause mortality at 1 year · people with endocarditis due to Staphylococcus aureus in drug abusers
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality (all‐cause) ‐ not reported · People with a haematological disorder
1 finding from 1 review
Overall survival (reported as mortality) · high‐risk neuroblastoma patients treated with autologous HSCT
Retinoic acid postconsolidation therapy showed no clear difference in overall survival (reported as mortality) compared with no further treatment (low certainty).
1 finding from 1 review